about
A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cellsProtein serine/threonine phosphatase Ptc2p negatively regulates the unfolded-protein response by dephosphorylating Ire1p kinase.Interaction of two actin-binding proteins, synaptopodin and alpha-actinin-4, with the tight junction protein MAGI-1The endoribonuclease activity of mammalian IRE1 autoregulates its mRNA and is required for the unfolded protein responseThe cellular response to protein misfolding in the endoplasmic reticulum.Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.Gene induction in response to unfolded protein in the endoplasmic reticulum is mediated through Ire1p kinase interaction with a transcriptional coactivator complex containing Ada5pThe adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias.ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.Conservation and divergence of the yeast and mammalian unfolded protein response. Activation of specific mammalian endoplasmic reticulum stress element of the grp78/BiP promoter by yeast Hac1.Positive allosteric modulation of the adenosine A2a receptor attenuates inflammation.O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.Enhancement of inosine-mediated A2AR signaling through positive allosteric modulation.On the regulation of Na+/H+ and K+/H+ antiport in yeast mitochondria: Evidence for the absence of an Na+-selective Na+/H+ antiporterEGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone ratsConformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitorsC-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetesDesign, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes
P50
Q24309442-283025F2-A2A8-430F-8EB6-2F98B7F80CA5Q27931120-80D1CBCD-7F66-4ACC-BE10-17A2DE30BEB3Q28202074-F056D574-927A-4D99-9EE2-F7C2D5726F51Q28646118-7EF11170-87A2-4796-A3D5-11D833DBD7DDQ33706901-DE0918B5-C504-4455-A51B-5A8356316A54Q35011697-9AD42351-0ECC-4071-A664-3BEE29E8ED67Q36127894-8F91A7BD-D9BE-4184-89FB-B5046B2643F0Q36784329-C47A8E5D-7C22-4D3D-B856-EA4076890690Q39688592-76427EF7-E397-4B21-AFCA-E167EE8A03A9Q41696201-634C46E2-D478-45B1-B7E7-D21425BAB99CQ43052140-B774998D-3B7D-42AD-9C7D-507263986B12Q43287659-A5A3F6D9-297B-4A8E-B0E0-B5A23FAE7F70Q50064386-10F174AC-E451-4C34-8FCC-CB3F6F45DF13Q58500348-83F7E2FD-32AE-4499-AD1C-6657F957C310Q83151540-99FAE48F-D031-4B3D-9B98-0826612CE1BDQ84100218-27ED4DBF-6452-4D30-9D95-5CD3D06F3FCCQ84518642-F53E2CCE-D38A-4E17-B217-E5B2B28ACB69Q87152477-8E7D5D10-1A67-4B2B-B4AA-F1452A71C66B
P50
description
researcher
@en
name
A A Welihinda
@ast
Ajith Welihinda
@en
Ajith Welihinda
@nl
type
label
A A Welihinda
@ast
Ajith Welihinda
@en
Ajith Welihinda
@nl
altLabel
A A Welihinda
@en
prefLabel
A A Welihinda
@ast
Ajith Welihinda
@en
Ajith Welihinda
@nl
P106
P31
P496
0000-0002-0049-0850